Maven Securities LTD Invests $1.11 Million in Jade Biosciences, Inc. $JBIO

Maven Securities LTD acquired a new stake in shares of Jade Biosciences, Inc. (NASDAQ:JBIO) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the company’s stock, valued at approximately $1,111,000. Maven Securities LTD owned about 0.08% of Jade Biosciences as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in JBIO. Legal & General Group Plc bought a new position in Jade Biosciences during the second quarter valued at about $29,000. Russell Investments Group Ltd. bought a new stake in shares of Jade Biosciences in the 2nd quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new stake in shares of Jade Biosciences during the 2nd quarter worth approximately $32,000. California State Teachers Retirement System grew its holdings in shares of Jade Biosciences by 40.3% during the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock worth $44,000 after purchasing an additional 819 shares in the last quarter. Finally, Group One Trading LLC increased its position in shares of Jade Biosciences by 122.9% during the fourth quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock valued at $65,000 after purchasing an additional 22,527 shares during the period.

Analysts Set New Price Targets

A number of research analysts recently commented on JBIO shares. UBS Group initiated coverage on Jade Biosciences in a research note on Monday, June 15th. They issued a “buy” rating and a $45.00 target price for the company. BTIG Research boosted their price target on shares of Jade Biosciences from $74.00 to $77.00 and gave the company a “buy” rating in a report on Monday, August 10th. Piper Sandler set a $55.00 price objective on shares of Jade Biosciences in a research note on Tuesday, June 2nd. Weiss Ratings downgraded shares of Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Finally, Wedbush lifted their target price on shares of Jade Biosciences from $45.00 to $47.00 and gave the company an “outperform” rating in a research report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $51.75.

Jade Biosciences Price Performance

Jade Biosciences stock opened at $19.45 on Wednesday. The company has a market capitalization of $1.24 billion, a PE ratio of -10.13 and a beta of 1.45. Jade Biosciences, Inc. has a one year low of $6.91 and a one year high of $28.00. The business has a 50 day simple moving average of $21.25 and a 200 day simple moving average of $19.50.

Jade Biosciences (NASDAQ:JBIO) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.10). Equities analysts anticipate that Jade Biosciences, Inc. will post -2.84 earnings per share for the current fiscal year.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.